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NUT Midline Carcinoma in a Pregnant Woman
D’Souza, JN1; Curry, JM1; Cognetti, DM1; Heffelfinger, RN1; Evans, JJ2,1; Tuluc, M3; Bilyk, JR4; Rosen, M1,2
1. Department of Otolaryngology-Head and Neck Surgery, 2. Department of Neurological Surgery, 3. Department of Anatomic and Surgical Pathology,Thomas Jefferson University Hospital,
Philadelphia PA, 4. Skull Base Division, Neuro-Ophthalmology Service, Wills Eye Hospital, Philadelphia, PA
ABSTRACT
NUT midline carcinoma is a rare, highly aggressive tumor that involves midline structures,
particularly in the head, neck and mediastinum. It is characterized by NUT gene
translocations on chromosome 15. It typically impacts teenagers or young adults, and has
a fulminant course leading to death in less than a year in most cases despite aggressive
chemoradiotherapy. Due to its location, this tumor is frequently considered inoperable. We
present a case of a sinonasal NUT midline carcinoma with orbital invasion discovered
during the workup of sinusitis in a young, pregnant woman. The tumor was managed with
definitive excision to negative margins followed by aggressive chemoradiation, with no
evidence of recurrence for 12 months. We propose that diagnosis of NUT midline
carcinoma should prompt recognition of the limitations of current medical therapy and rapid
surgical intervention should be undertaken when possible.

PATHOLOGY

DISCUSSION

Biopsy of the mass showed a malignant epithelial neoplasm with squamous features.
Immunoprofiling was carried out, with positive staining for the markers of squamous
differentiation, p16, and NUT antibody markers. Both histologic features (Fig 3A) and
immunochemical profile (Fig 3B) confirmed the diagnosis of NUT midline carcinoma.

NUT midline carcinoma (NMC) involves structures of the midline either in the thorax/mediastinum
(57%) or within the head and neck (35%), with isolated cases of other organ involvement1. NMC
has been considered a disease of children and adolescents2, though these tumors have been
reported across a wide age range (0-78 years) with a mean of 23 years at age of diagnosis.
NMC is genetically defined by the presence of a translocation on the nuclear protein in the testis
(NUT) gene on chromosome 5. In approximately two thirds of these cases, NUT is fused to BRD4
as a t(15;19) (q14;13.1) translocation. Head and neck lesions in particular demonstrate the BRD4NUT translocation in 88% of cases 3,4.

CASE REPORT
A 32 year old, 27 week pregnant female presented to her primary care doctor for evaluation
of a two month history of worsening nasal congestion, facial pressure, and rhinorrhea
refractory to antibiotics. Her symptoms also included right periorbital edema without vision
changes. Her medical history was significant for hypothyroidism, but no history of
immunosuppression or malignancy. There was no history of prior tobacco use. Given her
worsening symptoms despite maximal medical therapy, a CT of the midface (Fig 1) was
obtained, demonstrating a large right-sided nasal mass involving the adjacent paranasal
sinuses and right orbit. MRI of the orbits, face, and neck (Fig 2) was obtained for soft tissue
characterization, and further demonstrated right orbital extension inferiorly and medially,
with tumor adjacent to optic nerve. Pre-operative imaging also revealed the presence of an
enlarged right level II node.

Fig 1 CT maxillofacial coronal (left) and axial (right) views. A large mass is causing panopacification of right
sided sinuses and bone erosion. A small dehiscence of the right skull base is seen on coronal view.

Fig 3. A. Infiltrative, high grade squamous carcinoma showing abrupt transition from undifferentiated cells to well differentiated, mature
appearing squamous cells. Tumor necrosis, nuclear atypia and mitotic activity are present (hematoxilin eosin, original magnification 40x).
B. FISH analysis performed in Dr. Christopher French’s laboratory at the Brigham and Women’s Hospital, Boston, Massachusetts
demonstrated the presence of NUT-BRD4 translocation. Split probes to the NUT and BRD4 genes have been used to demonstrate NUT
rearrangement.

TREATMENT
Given the complexity of the diagnosis in a young, pregnant patient, this case was reviewed
extensively at a Multidisciplinary Tumor Board Conference. The lack of standardized treatment
and history of poor response to traditional chemoradiation in association with the typically
fulminant course of NUT midline carcinoma led to a consensus recommendation for aggressive
surgical extirpation. Right orbital exenteration was carried out after intraoperative frozen section
samples confirmed intraorbital invasion into both inferior oblique and inferior rectus muscles.
Extensive sinonasal resection was carried out, with removal of involved skull base structures,
including the cribiform plate, fovea ethmoidalis, and underlying dura. Bilateral modified radical
neck dissection of levels I-IV was carried out. Given the extent of the resection, harvest of an
anterolateral thigh free flap was undertaken for reconstructive purposes. A maternal fetal
medicine team was present in the operating suite for continuous fetal monitoring. Both the patient
and the fetus remained stable throughout the case and experienced no intraoperative or
postoperative complications. All surgical margins were negative on final pathology and neck
lymph nodes showed no evidence of local spread.

Recent research into targeted molecular therapy has opened new avenues for treatment of NMC.
Bromodomain inhibitor therapy in a dose escalation phase is undergoing clinical trials, and is
usually reserved for patients with recurrent or metastatic disease. Other promising therapies
include acetyl-histone mimics (BETi) and histone deacytelase inhibitors (HDACi)1,6.
In adults, NUT midline carcinoma is an underreported variant of poorly differentiated squamous
cell carcinoma. With the increased clinical awareness of this diagnosis and wider availability of
immunohistochemical staining, we anticipate increasing numbers of NMC cases in the future.
Early aggressive therapy is warranted to provide the best chance of disease-free survival.
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Fig 2. T1-weighted MRI orbits, face and neck, coronal (left) and T-2 weighted axial image (right)
demonstrating orbital extension of the tumor.

The diagnosis of NMC is associated with a grim prognosis, with fewer than 20% of those
diagnosed expected to survive to 1 year after diagnosis3. The median life expectancy is 6.7
months. Treatment options have focused on traditional chemoradiation. Surgical extirpation is
often not considered due to the presence of metastatic disease or primary site involvement that is
deemed unresectable because of involvement of critical structures. A 2012 review of 64 cases by
Bauer et al suggests that it is likely this diagnosis is underreported in adults3: because NMC is
considered a disease of the young, adult tissue is typically not sent for the cytogenetic and
molecular testing needed to establish the diagnosis.
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